Allergy seeks partners as FDA lifts hold on pollen vaccine
This article was originally published in Scrip
Executive Summary
The US FDA has confirmed that the 2007 clinical hold placed on Allergy Therapeutics' clinical development programme for its grass pollen allergy vaccine, Pollinex Quattro Grass (0.5ml; also known as Grass MATA MPL), has now been lifted with immediate effect, the has company said.